Turkish biotech startup raises $12M in Series A investment round
RS Research, a biotechnology startup that has raised $12 million in a Series A investment tour from companies in Turkey, has become an inspiration to…
Biotech Hub
Drugmakers seek tweaks to ICH guidance on continuous manufacturing
Eli Lilly, Gilead, Thermo Fisher and other industry groups and nonprofits like BIO and USP are seeking some slight changes and more clarity from the International Council of Harmonisation on its new…
US blacklists Chinese research institutes over ‘brain control’ efforts as investor frets roil biotech stocks
The US government is blacklisting a group of research institutes in China for using ‘biotechnology processes to support Chinese military end uses and end users, to include purported brain-control…
IN8bio’s ‘off-the-shelf’ gamma delta T cells stave off relapse for high-risk leukemia patients in very early data cut
With eyes set on the future of cell therapy, researchers are looking to leverage a growing menagerie of immune cells to engineer a better generation of tumor fighters. One type showing early promise…
Uncoordinated and redundant: FDA’s Pazdur slams checkpoint inhibitor developers for creating a ‘Wild West’
There’s no denying that Merck’s Keytruda set a high bar for checkpoint inhibitors in development everywhere. But when it comes to the often redundant development of PD(L)-1 antibodies worldwide, FDA’s…
Singapore to get a new manufacturing, R&D site to fight help infectious diseases
Hilleman Laboratories is opening a vaccine and biologics development hub in Singapore to aid the company’s journey to develop affordable vaccines against infectious diseases. A 30,000-square-foot site will go up at 138 Depot Road in Biopolis at a brand new R&D center at the Biopolis industrial park. The project will
FDA seeks FTC action after rejecting petition to block first generics for decades-old vasopressin
The FDA on Wednesday not only approved the first generic versions of the decades-old diabetes insipidus treatment vasopressin, but also simultaneously offered a particularly damning rebuke of a…
The next-gen IL-2 race heats up as Anaveon secures a megaround with its sights set on mid-stage tests
There appears to be no shortage of cash for those in the hunt for a better IL-2. On Thursday, Swiss-based Anaveon raked in another $119 million to see its own candidate into a series of Phase II…
Calliditas nabs accelerated OK for rare kidney disease, beating two competitors to the punch
Since its founding, Calliditas has wagered it could bring to market a new formulation of an oral steroid to treat a rare kidney disease. And on Wednesday afternoon, its bet paid off. The FDA granted…
Alice Zhang’s ‘all-in-human’ AI and genomics upstart scores a $98M Series B
Just a few months after California AI and genomics player Verge Genomics partnered with Eli Lilly in a $700 million-plus biobucks deal for 4 neurological programs, the biotech has finished raising its…